Develops regenerative medicine products and therapies using cell and tissue protocols. Primarily focuses on therapies involving adult stem cells. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 67% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 10.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 17% of them.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 67% a year on average.
Sales run at $360K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 25 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $14.2M against $360K in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, BRTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BRTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.